Stay updated on Grapiprant and Pembrolizumab in NSCLC Clinical Trial

Sign up to get notified when there's something new on the Grapiprant and Pembrolizumab in NSCLC Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Grapiprant and Pembrolizumab in NSCLC Clinical Trial page

  1. Check
    yesterday
    No Change Detected
  2. Check
    8 days ago
    Change Detected
    Summary
    No substantive changes to the Study Details page were detected; all key sections and information remain as in the previous view.
    Difference
    0.5%
    Check dated 2025-11-03T00:44:59.000Z thumbnail image
  3. Check
    15 days ago
    No Change Detected
  4. Check
    37 days ago
    Change Detected
    Summary
    Updated version to v3.2.0 and added a government-operating-status notice; removed the prior v3.1.0 tag.
    Difference
    4%
    Check dated 2025-10-05T07:23:09.000Z thumbnail image
  5. Check
    44 days ago
    Change Detected
    Summary
    Version bump from v3.0.2 to v3.1.0; no other content changes detected.
    Difference
    0.1%
    Check dated 2025-09-28T02:55:02.000Z thumbnail image
  6. Check
    58 days ago
    Change Detected
    Summary
    Revision updated from v3.0.1 to v3.0.2. The 'Back to Top' element was removed; no other substantive changes to pricing, stock, or core content.
    Difference
    0.2%
    Check dated 2025-09-13T16:58:55.000Z thumbnail image
  7. Check
    65 days ago
    Change Detected
    Summary
    The web page has been updated from version 3.0.0 to version 3.0.1, indicating a revision in the content. Additionally, a 'Back to Top' feature has been added for improved navigation.
    Difference
    0.2%
    Check dated 2025-09-06T14:30:36.000Z thumbnail image
  8. Check
    73 days ago
    Change Detected
    Summary
    The web page has added a facility name and location while removing extensive information related to lung cancer and various medical terms, including the deletion of pembrolizumab, which is significant in cancer treatment.
    Difference
    4%
    Check dated 2025-08-30T11:19:27.000Z thumbnail image

Stay in the know with updates to Grapiprant and Pembrolizumab in NSCLC Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Grapiprant and Pembrolizumab in NSCLC Clinical Trial page.